Home＞BUSINESS
Meiji Grants Carbapenem Rights to Spero Outside Japan, Asia(Oct.13.2017)
Meiji Seika Pharma has sealed a licensing deal with Spero Therapeutics, granting the US biotech worldwide development and commercialization rights for tebipenem pivoxil, an oral form of a carbapenem-class antibiotic, excluding Japan and 13 Asian countries, the two companies said ...
(LOG IN FOR FULL STORY)
-
- JAK Inhibitor Battle for Atopic Dermatitis Intensifying, 1st Japan Filing Might Be Near Oct.17
- Eisai Seals Latin America Pact for Belviq Oct.17
- Teva Takeda Launches Voluntary Recall for Taxotere Generics Oct.17
- Chugai’s Satralizumab Cuts Relapse Risk of Neuromyelitis Optica Spectrum Disorder Oct.16
- Ono Joins GHIT Fund as 21st Funding Partner Oct.16
- JAK Inhibitor Battle for Atopic Dermatitis Intensifying, 1st Japan Filing Might Be Near(Oct.17)
- MHLW Lifts Contraindications for Combined Statin-Fibrate Use in Renal-Impaired Patients(Oct.17)
- Eisai Seals Latin America Pact for Belviq(Oct.17)
- Teva Takeda Launches Voluntary Recall for Taxotere Generics(Oct.17)
- ADR Victim Relief Claims Fall below 1,500 in FY2017: MHLW(Oct.17)
